Suppr超能文献

肺癌化疗患者静脉血栓栓塞症的发生率及其与死亡率的关系:一项回顾性数据库研究。

Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study.

机构信息

Boston Health Economics, Inc., 20 Fox Road, Waltham, MA 02451, USA.

出版信息

J Thromb Thrombolysis. 2012 Nov;34(4):446-56. doi: 10.1007/s11239-012-0741-7.

Abstract

Cancer patients, especially those with lung cancer and undergoing chemotherapy, have an elevated risk for venous thromboembolism (VTE). This study assessed incidence, timing, and risk factors for VTE (specifically receipt of chemotherapy), along with the association between VTE and survival among lung cancer patients receiving chemotherapy. Using Florida Medicaid administrative claims data (2000-2008), patients with any diagnosis of primary lung cancer were selected. Patients with recent prior VTE and those enrolled in Medicare or an HMO were excluded. Crude rates of VTE per 100 person years were estimated, and Cox proportional hazards models were developed to assess risk factors for VTE in the lung cancer population, and the association between VTE and survival among patients undergoing chemotherapy. Of 15,749 lung cancer patients, 7,052 (2,242 receiving chemotherapy and 4,810 not receiving chemotherapy) met cohort selection criteria. The incidence of VTE was 10.8 per 100 person-years (PYs) in the chemotherapy cohort and 6.8 per 100 PYs in the non-chemotherapy cohort. Among patients on chemotherapy developing VTE, median time to occurrence was 109 days, with 61 and 82 % of patients experiencing an event within six and 12 months, respectively. In multivariate analyses, the adjusted risk of VTE was 30 % higher among patients undergoing chemotherapy. Comorbidity and the presence of a central venous catheter also were significantly associated with a greater risk of developing VTE. Moreover, patients in the chemotherapy cohort who developed VTE had a significantly faster time-to-death (adjusted hazard ratio [HR] = 1.97; 95 % CI 1.69-2.29).VTE was common among lung cancer patients, especially among patients receiving chemotherapy, with the majority of VTE events occurring within 6 months of initiation of chemotherapy. The presence of a VTE event was significantly associated with an increased risk of mortality.

摘要

癌症患者,尤其是肺癌患者和正在接受化疗的患者,静脉血栓栓塞(VTE)的风险增加。本研究评估了 VTE(特别是接受化疗)的发生率、时间和危险因素,以及 VTE 与接受化疗的肺癌患者生存之间的关联。使用佛罗里达州医疗补助管理索赔数据(2000-2008 年),选择了任何原发性肺癌诊断的患者。排除了最近有 VTE 病史和参加医疗保险或 HMO 的患者。估计每 100 人年的 VTE 粗发生率,并建立 Cox 比例风险模型,以评估肺癌人群中 VTE 的危险因素,以及 VTE 与接受化疗的患者生存之间的关联。在 15749 名肺癌患者中,有 7052 名(2242 名接受化疗,4810 名未接受化疗)符合队列选择标准。化疗队列中 VTE 的发生率为每 100 人年 10.8 例(PYs),非化疗队列中为 6.8 例。在接受化疗发生 VTE 的患者中,中位发生时间为 109 天,分别有 61%和 82%的患者在 6 个月和 12 个月内发生事件。在多变量分析中,接受化疗的患者 VTE 的调整风险增加了 30%。合并症和中央静脉导管的存在也与发生 VTE 的风险显著增加相关。此外,在化疗队列中发生 VTE 的患者的死亡时间明显更快(调整后的危险比[HR] = 1.97;95%CI 1.69-2.29)。VTE 在肺癌患者中很常见,尤其是在接受化疗的患者中,大多数 VTE 事件发生在开始化疗后 6 个月内。VTE 事件的发生与死亡率增加显著相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验